Dailypharm Live Search Close

Hanmi & Organon maintain ₩70 billion worth contract

By Kim, Jin-Gu | translator Choi HeeYoung

21.08.17 17:21:14

°¡³ª´Ù¶ó 0
Co-sale with existing MSD

Continued copromotion such as Propecia, Proscar, and Fosamax


Hanmi has maintained a copromotion contract with Organon, which is separated from MSD.

According to the Financial Supervisory Service on the 18th, Hanmi signed a domestic copromotion contract with Organon in the second quarter. The contract is due at the end of this year. The items include hair loss treatment Propecia, prostate hypertrophy treatment Proscar, and osteoporosis treatment Fosamax. The total amount of prescriptions last year amounted to ₩67.7 billion. Propsia's prescription amount is ₩41.3 billion, Prosca's prescription amount is ₩14.3 billion, and Fosamax's prescription amount is ₩12.2 billion.

Hanmi had already signed a contract with MSD to promote i

Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)